Loading view.
Industry Symposium
Featured Industry Symposium
IS01: Join us to hear thought leaders discuss a newly approved combination therapy that includes RYBREVANT® (amivantamab-vmjw)
Room 20BC, San Diego Convention Center
Presented by Johnson & Johnson
Industry Symposium
IS02: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Room 33ABC, San Diego Convention Center
Presented by Amgen
Industry Symposium
IS04: A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
Room 20D, San Diego Convention Center
Presented by Merck & Co., Inc.
Industry Symposium
IS07: Emerging Therapies in Clinical Practice: What Are the Patient Perspectives on the Future of Lung Cancer Treatment?
Room 30DE, San Diego Convention Center
Presented by Boehringer Ingelheim
Industry Symposium
IS08: New Treatment Approach for HER2+ (IHC3+) Metastatic Solid Tumors After Prior Systemic Treatment
Room 20A, San Diego Convention Center
Presented by Daiichi Sankyo and AstraZeneca
Industry Symposium
IS10: LORBRENA® (lorlatinib): Overview of CROWN Trial Efficacy and Safety Data
Room 20BC, San Diego Convention Center
Presented by Pfizer Oncology
Industry Symposium
IS11: Un-Met Needs in NSCLC: The Emerging Potential Role of ADCs Targeting c-Met
Room 33ABC, San Diego Convention Center
Presented by AbbVie
Featured Industry Symposium
IS13: Accelerating Treatment Initiation with Next-Day NGS: Insights from a Multidisciplinary Collaboration Program in Precision Oncology
Room 33ABC, San Diego Convention Center
Presented by Thermo Fisher Scientific
Industry Symposium
IS16: Actionable Biomarkers in Early-Stage NSCLC
Room 33ABC, San Diego Convention Center
Presented by Roche Diagnostics